Fiocruz lidera ensaio clínico da OMS para combater Covid-19 no Brasil


Além do estudo, realizado em parceria com 18 hospitais de todas as regiões do Brasil, a fundação também está construindo um centro hospitalar de referência no RJ

Fonte: Fiocruz lidera ensaio clínico da OMS para combater Covid-19 no Brasil

OMS lança estudo global para testar 4 medicamentos contra Covid-19


Médicos do mundo todo poderão participar da pesquisa, que busca investigar a eficácia de remédios já conhecidos para tratar a infecção pelo novo coronavírus

Fonte: OMS lança estudo global para testar 4 medicamentos contra Covid-19

Cloroquina, usada contra a malária, será testada para tratar coronavírus nos EUA


Um medicamento passou a chamar a atenção nesta quinta-feira, após o presidente dos Estados Unidos, Donald Trump, anunciar que a FDA teria aprovado uma droga para o tratamento no país: a hidroxicloroquina.

Fonte: Cloroquina, usada contra a malária, será testada para tratar coronavírus nos EUA – Gizmodo Brasil

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19


https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=TOC

Medicamento para AIDS, usado por muito tempo e depois trocados por drogas mais palatáveis. Vinha sendo usado em vários países empiricamente para COVID-19.

Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial.

read_icon_512

Background: Gram-negative bacteremia is a major cause of morbidity and mortality in hospitalized patients. Data to guide the duration of antibiotic therapy are limited.

Methods: Randomized, multicenter, open-label, non-inferiority trial. Inpatients with Gram-negative bacteremia, afebrile and hemodynamically stable for at least 48 hours, were randomized to receive 7 (intervention) or 14 days (control) of covering antibiotic therapy. Patients with uncontrolled focus of infection were excluded. The primary outcome at 90 days was a composite of all-cause mortality; relapse, suppurative or distant complications; and re-admission or extended hospitalization (>14 days). The non-inferiority margin was set at 10%.

Results: We included 604 patients (306 intervention, 298 control) between January 2013 and August 2017 in three centers in Israel and Italy. The source of the infection was urinary in 411/604 (68%); causative pathogens were mainly Enterobacteriaceae (543/604, 90%). A 7-day difference in the median duration of covering antibiotics was achieved. The primary outcome occurred in 140/306 (45.8%) patients in the 7 days group versus 144/298 (48.3%) in the 14 days group (risk difference [RD] -2.6%, 95% confidence interval [CI] -10.5% to 5.3%). No significant differences were observed in all other outcomes and adverse events, except for a shorter time to return to baseline functional status in the short therapy arm.

Conclusions: In patients hospitalized with Gram-negative bacteremia achieving clinical stability before day 7, an antibiotic course of 7 days was non-inferior to 14 days. Reducing antibiotic treatment for uncomplicated Gram-negative bacteremia to 7 days is an important antibiotic stewardship intervention. (ClinicalTrials.gov number, NCT01737320).

 

WHO | Growing antibiotic resistance forces updates to recommended treatment for sexually transmitted infections

New guidelines for the treatment of 3 common sexually transmitted infections (STIs) were today issued by WHO in response to the growing threat of antibiotic resistance.

Fonte: WHO | Growing antibiotic resistance forces updates to recommended treatment for sexually transmitted infections